Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2025-08-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
关于最近五年被证券监管部门和交易所采取监管措施或处罚情况及整改情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Tianyu Biotech Co., Ltd. regarding regulatory measures and penalties imposed by securities regulatory authorities and stock exchanges over the past five years, along with the company's rectification actions. It references specific regulatory decisions, dates, and corrective measures but does not contain financial statements or detailed financial data. The document is a regulatory compliance announcement related to past regulatory actions and company responses, not a financial report or audit report. It is also not a report publication announcement since it contains substantive disclosure about regulatory measures and rectifications. Therefore, the document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-08-26 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report". It details the change in shareholding and voting rights of a specific shareholder (史东伟) in 天域生物科技股份有限公司, including the termination of a concerted action agreement and the waiver of voting rights. The document includes legal opinions, shareholder declarations, and detailed descriptions of the equity change. It is a formal disclosure of a change in major shareholding and voting rights, consistent with notifications required when significant shareholders alter their holdings or control status. There is no indication that this is an annual report, earnings release, or other financial report. The document is not a proxy solicitation, AGM material, or management report. It is a regulatory disclosure about a major shareholding change and voting rights announcement. Therefore, the most appropriate classification is Major Shareholding Notification (MRQ). The document length (9529 characters) and content confirm it is a full report, not just an announcement of a report.
2025-08-26 Chinese
前次募集资金使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds from a non-public stock issuance by the company 天域生物科技股份有限公司. It includes specifics on the amount raised, storage of funds, actual usage, investment projects, cash management, and returns on investment. The document references regulatory approval from the China Securities Regulatory Commission and includes financial figures and tables related to the fundraising and its application. This type of document is a specialized report on the use of capital raised, which fits the category of Capital/Financing Update (CAP). It is not an annual or interim report, audit report, or earnings release, but a focused update on fundraising and capital usage.
2025-08-26 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于天域生物科技股份有限公司详式权益变动报告书之财务顾问核查意见
Regulatory Filings
2025-08-26 Chinese
未来三年股东回报规划（2025年-2027年）
Regulatory Filings Classification · 90% confidence The document is titled '未来三年股东回报规划（2025年-2027年）' which translates to 'Future Three-Year Shareholder Return Plan (2025-2027)'. It details the company's profit distribution policy, principles, forms of dividend distribution, conditions and ratios for dividends, decision-making procedures, and mechanisms for profit distribution over the next three years. The document is a policy or plan regarding shareholder returns and dividend distribution rather than an announcement of dividend amounts or payment dates. It is not a short announcement or a report publication notice, nor does it contain financial statements or earnings data. It is a detailed plan related to dividends and shareholder returns, which fits best under the category of Notice of Dividend Amount (DIV) as it relates to dividend policy and shareholder returns planning. However, since it is a forward-looking dividend policy plan rather than a specific dividend amount announcement, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a regulatory disclosure about dividend policy and shareholder return planning that does not fit neatly into other categories like DIV (which is for specific dividend amount announcements). Therefore, the best classification is Regulatory Filings (RNS).
2025-08-26 Chinese
2025年度向特定对象发行A股股票募集资金使用可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025年度向特定对象发行A股股票募集资金使用可行性分析报告" which translates to "2025 Feasibility Analysis Report on the Use of Funds Raised from a Private Placement of A Shares." It discusses the planned use of funds from a specific stock issuance, including details on the number of shares, amount of funds to be raised, and the intended use of proceeds (supplementing working capital and repaying debt). The document includes financial ratios and analysis to justify the necessity and feasibility of the fundraising. It is not a full annual or interim financial report, nor is it an announcement of voting results or a regulatory filing. It is a detailed feasibility analysis report related to capital raising activities. Therefore, it fits best under the category Capital/Financing Update (CAP). The document length is 3429 characters, which is relatively short but contains substantive content about the capital raising plan and its financial impact, not just an announcement or notice. Hence, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2025-08-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.